FAIRFIELD, N.J., July 27 /PRNewswire-FirstCall/ -- BRADLEY PHARMACEUTICALS, INC. announced today that the Company’s A. Aarons subsidiary has launched authorized generic versions of therapies provided by Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals. As previously announced on January 4, 2006, A. Aarons was established to market authorized generic versions of therapies provided by Bradley’s operating units.
Orders are now being accepted for shipment of the following products: * Benzoyl Peroxide Cleanser 4.5% 400 mL * Benzoyl Peroxide Cleanser 6.5% 400 mL * Benzoyl Peroxide Cleanser 8.5% 400 mL * Urea 40% Cream 1 oz * Urea 40% Cream 3 oz * Urea 40% Cream 7 oz * Urea 35% Lotion 7 oz * Urea 35% Lotion 9 oz * Urea 50% Nail Gel 18 mL
Bradley President and CEO, Daniel Glassman, stated, “The launch of these products marks an important milestone for Bradley as we set out to capture market-share from versions of Doak and Kenwood brands that have previously been genericized. Additional generic product introductions are planned for Third Quarter 2006 and beyond, consistent with the Company’s life cycle management program for key Doak and Kenwood brands.”
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcement: July 26 - 30, 2006 - Doak Dermatologics will be exhibiting at the Summer Meeting of the American Academy of Dermatology, held in San Diego, CA. August 7 - 10, 2006 - Doak Dermatologics will be exhibiting at the American Podiatric Medical Association, held in Las Vegas, NV. Daniel Glassman will present at the RBC’s Healthcare Conference, to be held in New York City, December 12-14, 2006. Daniel Glassman will present at the Raymond James & Associates 28th Annual Institutional Investors Conference, to be held at the Hyatt Regency Grand Cypress in Orlando, FL., March 4-7, 2007.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as sales and earnings estimates, other predictions of financial performance, launches by Bradley of new products and market acceptance of Bradley’s products. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to estimate sales; ability to capture market-share of its branded and/or generic products; remediate its material weaknesses in its internal controls; maintain sales of its products; successfully acquire, develop, integrate, or sell new products, including POLYPHENON(R) E Ointment when and if approved by the FDA; or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations, Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com/
